KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Portfolio Pulse from
Krystal Biotech has received a positive opinion from the CHMP recommending the approval of its drug Vyjuvek for the treatment of dystrophic epidermolysis bullosa in the EU.
March 03, 2025 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's drug Vyjuvek has received a positive opinion from the CHMP, which is a significant step towards gaining EU approval for treating dystrophic epidermolysis bullosa.
The positive CHMP opinion is a critical regulatory milestone for Krystal Biotech, indicating a likely approval in the EU. This can lead to increased market potential and revenue for Vyjuvek, positively impacting KRYS stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100